Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.59 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.57 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.57 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.57 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.57 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.57 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.55 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.55 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.55 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.55 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.55 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ractopamine SCHEMBL27847115 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL8892153 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL350754 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL8851800 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL28026586 | 0.98 | ADRB2 (0.94) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL9757702 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL10659583 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Butopamine SCHEMBL122463 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL144797 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| Ractopamine SCHEMBL11471317 | 0.97 | ADRB2 (0.97) | ADRB2ADRB1ADRB3MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4734437-A | PHENETHANOLAMINES | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | claimed |
| CN-119286035-A | Corrosion-resistant aging-resistant flame-retardant ETFE film and preparation process thereof | 中建三局集团(深圳)有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-116574370-A | Durable antistatic high-strength polyamide engineering plastic and preparation method thereof | 杨魁明 | 2023-08-11 | — | — | CN | disclosed |
| CN-115716733-A | Coral reef repair material capable of controllably releasing coral pheromone and preparation method thereof | 三亚珊瑚礁生态研究所 | 2023-02-28 | — | — | CN | disclosed |
| US-8445542-B2 | Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals | BRIDGE PHARMA, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130090295-A1 | METHODS OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS | BRIDGE PHARMA, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8383685-B2 | Use of RR/SR-ractopamine | BRIDGE PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120065271-A1 | METHOD OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS | ABERG A K GUNNAR (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120015895-A1 | Use Of RR/SR-Ractopamine | BRIDGE PHARMA, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8071653-B2 | Use of RR/SR-ractopamine | BRIDGE PHARMA, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-5643967-A | ANIMAL GROWTH REGULATORS OF BETA-PHENETHANOLAMINES FOR FEED EFFICIENCY | ELI LILLY AND COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| US-5631298-A | B-PHENETHANOLAMINES | ELI LILLY AND COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-4992473-A | Beta-phenethanolamines | ELI LILLY AND COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0204948-B1 | GROWTH PROMOTION OF ANIMALS WITH PHENETHANOL AMINES | ELI LILLY AND COMPANY (US) | 1990-03-28 | — | — | EP | disclosed |
| US-4849453-A | ANIMAL GROWTH REGULATORS | ELI LILLY AND COMPANY (US) | 1989-07-18 | — | — | US | disclosed |
| US-4734437-A | PHENETHANOLAMINES | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4690951-A | B-PHENETHANGLAMINES; FEED EFFICIENCY AND LEANESS | ELI LILLY AND COMPANY (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0204948-A1 | Growth promotion of animals with phenethanol amines | ELI LILLY AND COMPANY (US) | 1986-12-17 | — | — | EP | disclosed |
| EP-0117647-A1 | Improvements in or relating to phenethanolamines | ELI LILLY AND COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
| EP-0007205-A1 | Optically active phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065271-A1 | METHOD OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS | PYGM, CPT1B, MTPN | ADRB2 11/4885ADRB1 5/4885ADRB3 16/4885 |
| US-20130090295-A1 | METHODS OF ACCELERATING MUSCLE GROWTH, DECREASING FAT DEPOSITS AND IMPROVING FEED EFFICIENCY IN LIVESTOCK ANIMALS | PYGM, CPT1B, MTPN | ADRB2 11/4885ADRB1 4/4885ADRB3 16/4885 |
| US-20120015895-A1 | Use Of RR/SR-Ractopamine | SRR, SRRM2, MTPN | ADRB2 19/4885ADRB1 7/4885ADRB3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.